Impact of IKZF1 Deletions on the Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for B-Cell Acute Lymphoblastic Leukemia

Our main purpose was to investigate if the chronic treatment with the disease-modifying drug natalizumab shows quantifiable effect on BDNF levels in multiple sclerosis patients.BDNF plasma concentration was evaluated using enzyme-linked immunosorbent assay in healthy individuals, not treated multiple sclerosis patients and patients treated with natalizumab.Multiple sclerosis patients have a significantly lower amount of peripheral BDNF than healthy individuals. Patients treated with natalizumab have significantly higher BDNF levels than not treated patients.Chronic natalizumab treatment is associated with significantly increased plasma BDNF concentration in multiple sclerosis.